本文来自彭博终端，终端用户可运行NSN T9SWR8KGCTG3 阅读原文。非终端用户可点击文末 "阅读原文" 预约演示。 彭博行业研究（Bloomberg Intelligence）就各公司、行业和市场提供全球投研分析以及交互 式数据。BI对ETF的研究覆盖全球市场，以深度、前沿、独特的视角为您展现ETF市场趋势， 分析热门课题，分享专业洞见。 本期主题： 大举投资Spac eX，亿万富豪Ron Baron为ETF领域开先河 （彭博行业研究）——Ba r o n First Pri n c i p l e s ETF (RONB)将马斯克旗下Sp a c eX在投资组 合中的权重大幅提高至2 2%，创下私募股权在ETF中权重的最高纪录，这只ETF可能将成为 主动型ETF领域的下一个"明星"。该基金还投资了马斯克的AI公司xAI以及生产汽车和人形 机器人的特斯拉，借此成为市场上对这位亿万富翁旗下极具创新力且成功企业敞口最大的 ETF。 扫描二维码 立即订阅 更多ETF精彩内容 RONB对私募股权的敞口不容忽视 通过大幅增持Sp a c eX，RONB开拓了一个新领域。目前Sp a c eX在该基金投资组合中的 ...

美国联邦政府的债务总额在2026年2月初达到了38.5万亿美元。 这个数字意味着，美国政府每分钟需要支付的国债利息就接近230万美元。 这笔利息支出， 在2026财年第一季度已经超过了同期国防预算，成为联邦财政的第二大支出项目。 国际货币基金组织在2026年2月25日发布的报告中警示，美国国债规模攀升正对全球经济稳定构成日益严峻的挑战。 该组织预测，若当前政策不变，到2031 年美国公共债务占国内生产总值的比重将升至140%。 Myrmikan Capital创始人丹尼尔·奥利弗在2026年2月26日接受采访时指出，过度杠杆化的私募股权与不断扩张的美国国债，正如"夹板"一样困住了美联储。 他认为，在当前的美元估值下，这些债务在数学上已经无法偿还。 奥利弗解释，2008年金融危机时，美联储可以通过印钱来重塑房地产市场，但救助私募股权行业则是另一回事。 那些因为消费需求不足而面临破产的高杠 杆公司，无法仅仅依靠向银行系统注入流动性来拯救。 这种系统性压力在私人信贷市场表现得尤为明显。 瑞银集团的分析师在2026年2月发出警告，在最坏的情况下，由于人工智能对企业借款人的快速颠覆，私 人信贷的违约率可能飙升至15%。 ...

"考虑到当前的利率水平以及进入和退出时的估值倍数，你需要在五年内每年增长12%才能获得相同的 回报，"她说。"12%是新的5%。" 优质资产已售罄，持有期延长 贝恩咨询报告指出，私募股权管理公司已出售了"宝石"级资产，但对前景不那么确定的资产则难以脱 手。全球私募股权公司目前拥有约3.2万家投资组合公司，资产持有期已从2021年的平均5至6年延长至 约7年。 私募股权行业正经历一场持续时间超过2008年金融危机的深度调整。贝恩咨询最新报告显示，该行业连 续第四年向投资者返还较少利润，同时坐拥3.8万亿美元未售出资产，新基金募资陷入困境。 2025年，私募股权分配占净资产价值的比例维持在14%，为2008年金融危机最严重时期以来的第二低水 平。尽管去年交易价值较前一年增长44%至9040亿美元，但这一增长几乎未能消化行业积压的巨额"干 火药"——即可用于投资的待部署资金。 贝恩咨询全球私募业务负责人Rebecca Burack在采访中表示，特朗普关税带来的不确定性突然刹停了交 易活动。就在2025年1月，交易势头看起来还"极其强劲"。 募资已连续四年下滑，2025年降至3950亿美元，同比下降16%。投资者变得 ...

私募股权返还给投资者的利润连续第四年减少，因该行业积压了3.8万亿美元的未售出资产，且难以为 新基金筹资。 贝恩公司新报告显示，去年，以净资产价值为基准的分配比例维持在14%——这是自2008年金融危机最 严重时期以来的次低水平。而当前低迷期的持续时间甚至比私募股权公司当时面临的困境更为严峻。 2025年交易总额较上年增长44%达到9040亿美元，主要得益于多宗大型交易，包括566亿美元的艺电公 司私有化。然而，这仅对该行业所谓的"干火药"（即可供投资的资金）造成了轻微影响。交易总量下降 6%至3018宗。 贝恩的全球私募业务主管Rebecca Burack接受采访时表示："并非所有人都觉得这是个好年头。"她表 示，美国总统唐纳德·特朗普"解放日"关税引发的不确定性突然叫停了交易活动，而就在去年1月，这些 交易还看起来"非常火爆"。 随着2022年利率开始上升，交易活动放缓，迫使私募股权基金经理减少向投资者返还的利润。这反过来 又削弱了公司筹集新资金的能力。2025年的募资额仍下降了16%至3950亿美元——连续第四年下滑—— 尽管投资者向专注于基础设施和二级市场的基金投入了更多资金。 该报告指出，养老基金和 ...

Investment Rating - The report indicates a positive outlook for the European private equity (PE) market, with expectations of continued growth in 2026 due to increased capital inflows and a more predictable macroeconomic environment [18]. Core Insights - The European PE market achieved a record year in 2025, with total transaction value increasing by 14.4% year-on-year and transaction volume rising by 12.8%, driven by improved macroeconomic conditions and renewed investor confidence [4][10]. - The share of mega-deals (transactions over €1 billion) rose to 31.9% of total transaction value, reflecting a return of sponsor confidence and risk appetite [19][22]. - The exit environment showed signs of improvement, with exit values increasing by 10% year-on-year, although still below the peak levels of 2021 [66][67]. Summary by Sections Transactions - In 2025, the European PE market recorded a historic year with transaction values reaching €645.3 billion, supported by favorable monetary policies and a stable macroeconomic backdrop [10][19]. - The average transaction size increased by 32.8%, from €238.1 million to €316.2 million, indicating a willingness to underwrite larger deals [20][22]. - The UK and Ireland accounted for 31.6% of total European transaction value, maintaining a significant lead in the PE market [38]. Exits - The total exit value in Europe reached €1,610 billion in 2025, marking a 10% increase from the previous year, although still 27.6% lower than the peak in 2021 [66][67]. - The second half of 2025 saw a notable improvement in exit momentum, with exit values in H2 being double that of H1 [67]. - The median holding period for PE portfolio companies decreased to 5.8 years, indicating improved exit mechanisms within portfolios [70]. Fundraising - Fundraising in the European PE market slowed in 2025, with a total of €80.8 billion raised, reflecting a trend of decreasing fund closures and stricter capital conditions [6][92]. - The concentration of fundraising efforts shifted towards established managers, with experienced firms accounting for 85.6% of the capital raised [6]. - The UK and Ireland remained the primary fundraising hubs, capturing nearly half of the total capital raised in Europe [6].

Core Insights - The global healthcare private equity market is experiencing a significant recovery and record growth, with total deal value expected to exceed $191 billion in 2025, marking a historical high [11][12][16] - The market shows clear regional differentiation, with Europe leading in biopharma and healthcare services, North America maintaining stability despite policy impacts, and Asia-Pacific demonstrating broad growth resilience [11][25][27] Market Performance - In 2025, healthcare private equity saw a record performance with disclosed deal value surpassing $191 billion and 445 buyouts, making it the second-highest annual total on record [11][12] - The exit value surged from $54 billion in 2024 to an expected $156 billion in 2025, driven by an increase in large deals [15][16] Regional Analysis - Europe experienced a doubling of deal value to approximately $59 billion, primarily driven by biopharma and healthcare provider deals [25] - North America faced a temporary pullback in the second quarter but still achieved a healthy year with an expected exit activity of $90 billion, significantly higher than 2024 [26] - Asia-Pacific set a record for deal value, exceeding 2021's high by over 30%, with notable growth in biopharma, medtech, and healthcare IT [27][28] Sector Trends - Biopharma remains a cornerstone of investment, with deal value rising from $55 billion in 2024 to an estimated $80 billion in 2025, accounting for about 30% of overall deal volume [33] - Provider and related services deal value increased by 57% to an estimated $62 billion, driven by technology-enabled assets and healthcare IT [38] - Medtech is emerging as a new growth engine, with investors focusing on revenue growth and margin expansion [39] Investment Strategies - The investment logic in healthcare IT is shifting towards revenue and profit expansion through refined pricing and generative AI applications, with the "60 rule" becoming a new performance benchmark [3] - Investors are adopting a "barbell strategy" in pharma services, focusing on high-quality assets with scale advantages and potential operational improvements [3]

Investment Rating - The report does not explicitly state an investment rating for the multi-financial industry or the specific company being analyzed [2]. Core Insights - The private equity business of the company is primarily executed by its wholly-owned subsidiary, with a management scale of approximately 26.7 billion and a cumulative management scale exceeding 33.7 billion [23]. - The investment focus is on high-end equipment, new energy, new materials, and intelligent manufacturing, with these sectors accounting for over 75% of the number of projects and 80% of the investment amount [23]. - The company has seen a significant increase in fund management scale in recent years, with government contributions rising to 30%-70% in newly established funds post-2021 [23]. - The overall MOIC (Multiple on Invested Capital) for all existing funds is approximately 1.45 times [24]. - The company has invested in around 150 projects, with 31 achieving IPO exits across various stock exchanges, including the Shanghai Stock Exchange and the Hong Kong Stock Exchange [26]. - The company anticipates launching 2-3 new funds in 2026, with a focus on industrial investment directions and collaboration with local governments and financial institutions [27]. - The company reported significant growth in the first three quarters of 2025, driven by improved profitability of its financial subsidiaries and substantial increases in equity investment income [27]. Summary by Sections 1. Basic Research Information - The research was conducted on January 22, 2026, focusing on the multi-financial industry and the company Zhejiang Dongfang [12][16]. 2. Detailed Research Institutions - Participating institutions included Guangfa Securities, CITIC Bank, Harvest Fund, BOC International, and Caitong Fund [17]. 3. Research Institution Proportions - The report does not provide specific data on the proportions of research institutions involved [22]. 4. Main Content Information - The private equity business is structured as a comprehensive ecosystem involving direct investment, mother funds, and industrial funds, with a focus on collaboration with AIC institutions and local government [23]. - The company has adjusted its investment strategy in response to changing market conditions, with a decrease in the minimum return threshold from 8% to 5%-6% [24]. - The company is exploring various exit strategies due to market environment impacts, with a focus on maintaining a steady operational performance and optimizing asset structure for sustainable profitability [27].

Group 1: Market Overview - The global healthcare private equity (PE) market experienced a strong recovery in 2025, achieving record growth with disclosed deal value exceeding $191 billion, surpassing the previous peak in 2021 [14][19] - A total of approximately 445 transactions were recorded, marking the second-highest annual total in history [14][19] - Exit activity also rebounded significantly, with exit value reaching an estimated $156 billion, up from $54 billion in 2024, driven by an increase in large transactions [18][19] Group 2: Regional Performance - In Europe, deal value doubled to approximately $59 billion, primarily driven by biopharma and healthcare services transactions [28] - North America saw a temporary pullback in the second quarter due to macroeconomic uncertainties, but still achieved a healthy exit value of around $90 billion, significantly higher than 2024's $35 billion [29] - Asia-Pacific set a record for deal value, exceeding 2021's high by more than 30%, with notable growth in biopharma, medtech, and healthcare IT [30][31] Group 3: Sector Insights - Biopharma remained a core focus, with deal value rising to an estimated $80 billion, accounting for about 30% of overall deal volume [36] - Provider and related services saw a 57% increase in deal value to approximately $62 billion, driven by technology-enabled assets [41] - Medtech experienced significant growth, with deal value nearly doubling to an estimated $33 billion, reflecting investor interest in large-scale assets [42] Group 4: Deal Dynamics - Sponsor-to-sponsor transactions surged, with over 150 deals expected and more than $110 billion in estimated value, indicating a strong market [47] - High-value deals exceeding $1 billion contributed to the overall increase in average deal size, with more than 30 such transactions recorded in 2025 [54] - The healthcare IT sector continued to attract investment, accounting for nearly 20% of healthcare transactions in 2025, supported by strong fundamentals [62]

Group 1 - The US IPO market is on the verge of recovery, with an estimated $2.9 trillion worth of private companies expected to enter the public market by 2026, marking a significant turning point for capital markets [1] - The anticipated IPO wave includes notable tech giants like SpaceX, OpenAI, and Anthropic, as well as many lesser-known tech companies, driven by pent-up demand and expectations of a market rebound in 2026 [1][2] - The private equity (PE) industry may face "survival risks" as portfolio companies go public, testing the promised returns against real market prices, which could lead to a historic contraction in the industry [1][3] Group 2 - The recent downturn in the IPO market is attributed more to cyclical factors rather than structural issues, with high interest rates suppressing valuations and listing intentions [2] - Despite the likelihood of a high long-term interest rate environment, short-term rates are expected to decline, creating conditions for the return of IPO activities due to accumulated listing demand [2] - The private equity market, currently exceeding $16 trillion, has seen significant growth but faces pressure to return cash to investors, necessitating accelerated exits as companies go public [3] Group 3 - The long-term trend of declining IPO numbers since the early 2000s may be reversing, although returning to 1980s levels of IPO activity remains unlikely, indicating that public markets are still a vital financing channel for high-growth companies [4] - The upcoming IPO wave will primarily feature smaller companies, with concerns that heavily indebted marginal firms may struggle in the current investment environment [5] - The market's cautious sentiment towards the viability of AI-driven business models will be tested, as the IPOs will reveal investor enthusiasm and willingness to pay premiums for emerging technologies [5]

Group 1 - Private equity firms are selling assets to self-established continuation funds at a record pace, accounting for approximately one-fifth of total sales in 2025 [1][2] - The traditional exit channels for private equity firms remain constrained, prompting this shift in strategy [1][2]